Research

From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research


Reference:

Cassels, B. K., Bermudez, I., Dajas, F., Abin-Carriquiry, J. A. and Wonnacott, S., 2005. From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research. Drug Discovery Today, 10 (23-24), pp. 1657-1665.

Related documents:

This repository does not currently have the full-text of this item.
You may be able to access a copy if URLs are provided below.

Official URL:

http://dx.doi.org/10.1016/S1359-6446(05)03665-2

Abstract

S-Nicotine, the principal psychoactive constituent of Nicotiana tabacum, underpins addiction to tobacco smoking. Although tobacco consumption is a leading cause of death worldwide, nicotine itself is also proposed to have potential therapeutic benefits for a diverse range of conditions. Nicotine interacts with its cognate receptors in the central nervous system to exert a predominantly modulatory influence, making neuronal nicotinic receptors attractive therapeutic targets. Here, we focus on three natural products as lead compounds for drug discovery programs, nicotine, epibatidine and cytisine, and consider the aims and limitations that shape these drug discovery endeavors.

Details

Item Type Articles
CreatorsCassels, B. K., Bermudez, I., Dajas, F., Abin-Carriquiry, J. A. and Wonnacott, S.
DOI10.1016/S1359-6446(05)03665-2
DepartmentsFaculty of Science > Biology & Biochemistry
RefereedYes
StatusPublished
ID Code3859

Export

Actions (login required)

View Item